Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $370,000 Stock Holdings in Iqvia Holdings Inc (NYSE:IQV)

Share on StockTwits

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 842.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,394 shares of the medical research company’s stock after purchasing an additional 2,140 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Iqvia were worth $370,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Chesley Taft & Associates LLC lifted its position in shares of Iqvia by 1.2% in the third quarter. Chesley Taft & Associates LLC now owns 6,130 shares of the medical research company’s stock valued at $916,000 after buying an additional 75 shares during the last quarter. Montag & Caldwell LLC lifted its position in shares of Iqvia by 3.3% in the third quarter. Montag & Caldwell LLC now owns 2,840 shares of the medical research company’s stock valued at $424,000 after buying an additional 90 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its position in shares of Iqvia by 0.6% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 15,925 shares of the medical research company’s stock valued at $2,460,000 after buying an additional 93 shares during the last quarter. NEXT Financial Group Inc lifted its position in shares of Iqvia by 0.8% in the fourth quarter. NEXT Financial Group Inc now owns 12,941 shares of the medical research company’s stock valued at $2,000,000 after buying an additional 100 shares during the last quarter. Finally, Zeke Capital Advisors LLC lifted its position in shares of Iqvia by 4.7% in the third quarter. Zeke Capital Advisors LLC now owns 2,332 shares of the medical research company’s stock valued at $348,000 after buying an additional 104 shares during the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently issued reports on IQV. Wells Fargo & Co began coverage on Iqvia in a research report on Tuesday, January 7th. They issued an “overweight” rating and a $180.00 price objective for the company. Cfra raised Iqvia from a “sell” rating to a “hold” rating in a research report on Friday, December 13th. Credit Suisse Group reiterated a “buy” rating and set a $170.00 target price on shares of Iqvia in a research note on Friday, December 20th. Citigroup started coverage on Iqvia in a research note on Monday, January 6th. They set a “buy” rating and a $185.00 target price on the stock. Finally, Wolfe Research upgraded Iqvia from a “peer perform” rating to an “outperform” rating in a research note on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $169.10.

In other Iqvia news, Director Michael J. Evanisko sold 6,250 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $160.08, for a total value of $1,000,500.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Michael R. Mcdonnell sold 12,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.07, for a total value of $1,860,840.00. Following the completion of the sale, the chief financial officer now directly owns 14,366 shares in the company, valued at approximately $2,227,735.62. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,500 shares of company stock worth $3,866,090. Corporate insiders own 6.00% of the company’s stock.

Iqvia stock opened at $160.50 on Friday. The stock’s fifty day moving average price is $154.00 and its two-hundred day moving average price is $151.64. Iqvia Holdings Inc has a one year low of $123.57 and a one year high of $164.13. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.12 and a quick ratio of 1.12. The firm has a market cap of $31.14 billion, a PE ratio of 131.56, a price-to-earnings-growth ratio of 1.70 and a beta of 0.88.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $1.60 EPS for the quarter, topping the Zacks’ consensus estimate of $1.57 by $0.03. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.76 billion. During the same quarter last year, the company earned $1.42 EPS. The company’s revenue was up 6.7% on a year-over-year basis. Sell-side analysts expect that Iqvia Holdings Inc will post 5.9 earnings per share for the current fiscal year.

Iqvia Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: What is a capital gain?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.